1342896-73-4

Basic information

• Product Name: 2-Propanol, 1-[(2-broMo-5-fluoro-4-nitrophenyl)aMino]-3-(phenylMethoxy)-, (2R)-
• Synonyms: 2-Propanol, 1-[(2-broMo-5-fluoro-4-nitrophenyl)aMino]-3-(phenylMethoxy)-, (2R)-;2-Propanol, 1-[(2-broMo-5-fluoro-4-nitrophenyl)aMino]-3-(phenylMethoxy)-, (2R)-4
• CAS NO: 1342896-73-4
• Molecular Weight: 399.216
• Mol File: 1342896-73-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-Propanol, 1-[(2-broMo-5-fluoro-4-nitrophenyl)aMino]-3-(phenylMethoxy)-, (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propanol, 1-[(2-broMo-5-fluoro-4-nitrophenyl)aMino]-3-(phenylMethoxy)-, (2R)-(1342896-73-4)
• EPA Substance Registry System: 2-Propanol, 1-[(2-broMo-5-fluoro-4-nitrophenyl)aMino]-3-(phenylMethoxy)-, (2R)-(1342896-73-4)

Safety Data

• Hazardous Substances Data: 1342896-73-4(Hazardous Substances Data)

Upstream product

• 952664-69-6 2-bromo-5-fluoro-4-nitroaniline 
• 14618-80-5 (R)-benzyl glycidol 
• 2369-13-3 3-fluoro-4-nitroaniline 
• 2930-05-4 (S)-benzyl glycidyl ether 

Downstream Products

• 1294504-68-9 N-{1-[(2R)-3-(benzyloxy)-2-hydroxypropyl]-2-[1-(benzyloxy)-2-methylpropan-2-yl]-6-fluoro-1H-indol-5-yl}-1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)cyclopropane-1-carboxamide 
• 1294504-66-7 (R)-1-((4-amino-2-(4-(benzyloxy)-3,3-dimethylbut-1-yn-1-yl)-5-fluorophenyl)amino)-3-(benzyloxy)propan-2-ol 
• 1294504-67-8 (2R)-1-{5-amino-2-[1-(benzyloxy)-2-methylpropan-2-yl]-6-fluoro-1H-indol-1-yl}-3-(benzyloxy)propan-2-ol 
• 1152311-62-0 (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide 
• 1294504-64-5 (R)-1-((4-amino-2-bromo-5-fluorophenyl)amino)-3-(benzyloxy)propan-2-ol p-toluenesulfonic acid salt 
• 1294504-63-4 (R)-1-(4-amino-2-bromo-5-fluorophenylamino)-3-(benzyloxy)propan-2-ol 

Relevant articles and documents

Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases

The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.

CYCLOPROPANECARBOXAMIDE MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention relates to new cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator proteins, pharmaceutical compositions thereof, and methods of use thereof.

PHARMACEUTICAL COMPOSITIONS OF (R)-1-(2,2-DIFLURORBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL) CYCLOPROPANECARBOXAMIDE AND ADMINISTRATION THEREOF

A pharmaceutical composition comprising Compound 1, (R)- 1 -(2,2- difluorobenzo[d] [ 1,3]dioxol-5-yl)-N-( 1 -(2,3-dihydroxypropyl)-6-fluoro-2-( 1 -hydroxy-2- methylpropan-2-yl)- l H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from : a filler, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed.